Intercept Pharmaceuticals (NASDAQ:ICPT) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($2.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.65) by $0.47, MarketWatch Earnings reports. The business had revenue of $47.00 million during the quarter, compared to analyst estimates of $48.24 million. Intercept Pharmaceuticals had a negative net margin of 215.30% and a negative return on equity of 614.15%. The firm’s revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.89) earnings per share. Intercept Pharmaceuticals updated its FY 2018 guidance to EPS.
Shares of ICPT stock opened at $96.01 on Thursday. Intercept Pharmaceuticals has a 12 month low of $51.05 and a 12 month high of $133.74. The company has a debt-to-equity ratio of 2.48, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market cap of $2.58 billion, a price-to-earnings ratio of -6.68 and a beta of -1.94.
Several equities analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, August 2nd. Wedbush reaffirmed a “buy” rating and set a $203.00 price objective (down previously from $217.00) on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. BidaskClub lowered shares of Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. ValuEngine raised shares of Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $115.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. Nine investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $139.88.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
See Also: How Short Selling Works
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.